Company Update (NYSE:BAX): Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398

[Business Wire] – DEERFIELD, Ill. & CAMBRIDGE, Mass.–(BUSINESSWIRE)– Baxter International Inc. (NYSE:BAX – News) and Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK – News) today jointly announced an exclusive license and collaboration agreement for the development . . . → Read More: Company Update (NYSE:BAX): Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 Similar Articles: Company Update: Baxter International Inc (NYSE:BAX) – Baxter Announces Baxalta as the Name of New Global Biopharmaceutical Company Market Update: Baxter International Inc (NYSE:BAX) – Baxter Announces Hemodialysis Dialyzer Expansion in Opelika, Alabama Stock Update: Baxter International Inc (NYSE:BAX) – Baxter to Present at Morgan Stanley Global Healthcare Conference